Antiangiogenic Treatment as a Pre-Operative Management of Alveolar Soft-Part Sarcoma

被引：14

作者：

Conde, Nuria ^{[1
]}

Cruz, Ofelia ^{[1
]}

Albert, Asteria ^{[2
]}

Mora, Jaume ^{[1
]}

机构：

[1] Hosp St Joan de Deu, Dept Paediat Oncol, Barcelona 08950, Spain

[2] Hosp St Joan de Deu, Dept Paediat Surg, Barcelona 08950, Spain

来源：

PEDIATRIC BLOOD & CANCER | 2011年 / 57卷 / 06期

关键词：

alveolar soft-part sarcoma; antiangiogenic treatment; bevacizumab; vascular endothelial growth factor (VEGF); SOLID TUMORS; BEVACIZUMAB; CANCER; VEGF; EXPRESSION; TONGUE;

D O I：

10.1002/pbc.23241

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Alveolar soft-part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue. Pediatr Blood Cancer 2011;57:1071-1073. (C) 2011 Wiley-Liss, Inc.

引用

页码：1071 / 1073

页数：3

共 13 条

[1] Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma [J].

Azizi, Amedeo A. ;

Haberler, Christine ;

Czech, Thomas ;

Gupper, Astrid ;

Prayer, Daniela ;

Breitschopf, Helene ;

Acker, Till ;

Slavc, Irene .

LANCET ONCOLOGY, 2006, 7 (06) :521-523

[2] Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study [J].

Bender, Julia L. Glade ;

Adamson, Peter C. ;

Reid, Joel M. ;

Xu, Lu ;

Baruchel, Sylvain ;

Shaked, Yuval ;

Kerbel, Robert S. ;

Cooney-Qualter, Erin M. ;

Stempak, Diana ;

Chen, Helen X. ;

Nelson, Marvin D. ;

Krailo, Mark D. ;

Ingle, Ashish M. ;

Blaney, Susan M. ;

Kandel, Jessica J. ;

Yamashiro, Darrell J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :399-405

[3] Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors [J].

Benesch, M. ;

Windelberg, M. ;

Sauseng, W. ;

Witt, V. ;

Fleischhack, G. ;

Lackner, H. ;

Gadner, H. ;

Bode, U. ;

Urban, C. .

ANNALS OF ONCOLOGY, 2008, 19 (04) :807-813

[4] Alveolar soft part sarcoma of the tongue [J].

Bentley, RP ;

Wake, MJC ;

Raafat, F .

BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 1999, 37 (06) :451-454

[5] Lingual alveolar soft part sarcoma; 14 cases: novel clinical and morphological observations [J].

Fanburg-Smith, JC ;

Miettinen, M ;

Folpe, AL ;

Weiss, SW ;

Childers, ELB .

HISTOPATHOLOGY, 2004, 45 (05) :526-537

[6] Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].

Ferrara, N ;

Hillan, KJ ;

Gerber, HP ;

Novotny, W .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400

[7] Primary alveolar soft-part sarcoma of the mediastinum: a clinicopathological and immunohistochemical study of two cases [J].

Flieder, DB ;

Moran, CA ;

Suster, S .

HISTOPATHOLOGY, 1997, 31 (05) :469-473

[8] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[9]

Jain Rakesh K, 2005, Oncology (Williston Park), V19, P7

[10] Lingual alveolar soft part sarcoma in a child managed successfully with surgery and chemotherapy [J].

Kumar, M. ;

Patne, S. ;

Vishwanath, A. ;

Hasan, Z. .

INDIAN JOURNAL OF CANCER, 2010, 47 (02) :234-235

← 1 2 →